Literature DB >> 16136377

Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.

Hirofumi Asakura1, Hitoshi Takashima, Masahiro Mitani, Reiji Haba, Reiko Seo, Koiku Yokoe, Yoshihiro Toyama, Motoomi Ohkawa.   

Abstract

Occult breast cancer presenting with axillary lymph node metastases is uncommon, and inflammatory breast cancer (IBC), as a subtype, is quite rare. Here we describe a case of IBC, which arose as an unknown primary carcinoma; the patient presented with axillary lymph node metastasis, and was successfully treated with trastuzumab and vinorelbine. Specifically, a 55-year-old woman presented with right axillary lymphadenopathy. Although she underwent various examinations, the primary site of the disease was not revealed. Axillary lymph node dissection was performed, and the lesion was diagnosed as a poorly differentiated adenocarcinoma. The patient chose to be treated by alternative medicine. About 6 months later, she was referred to our hospital, due to marked bilateral neck and axillary lymph node swelling. She presented with diffuse right breast enlargement, redness, and peau d'orange. Computed tomography (CT) of the breast showed skin thickening and swelling of the right breast.F-18 Fluorodeoxyglucose positron emission tomography (FDG-PET) showed FDG uptake in the right breast. The patient was clinically diagnosed with IBC. Because overexpression of the human epidermal growth factor receptor 2 (HER2) was found in the specimen from her right axillary lymph node, she was treated with trastuzumab and vinorelbine. Two months after the start of chemotherapy, CT revealed a complete response in the lymph nodes, and the skin thickening and parenchymal edema of the right breast had improved. FDG-PET was also performed at this time, and revealed no FDG uptake in either the right breast or the lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136377     DOI: 10.1007/s10147-005-0485-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  17 in total

Review 1.  New drugs for breast cancer.

Authors:  Ian E Smith
Journal:  Lancet       Date:  2002-09-07       Impact factor: 79.321

2.  Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon.

Authors:  J D'Emilia; K Bulovas; K D'Ercole; B Wolf; G Steele; I C Summerhayes
Journal:  Oncogene       Date:  1989-10       Impact factor: 9.867

3.  Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience.

Authors:  S A Aziz; S Pervez; S Khan; N Kayani; S I Azam; M H Rahbar
Journal:  Breast J       Date:  2001 Nov-Dec       Impact factor: 2.431

4.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.

Authors:  M Pegram; S Hsu; G Lewis; R Pietras; M Beryt; M Sliwkowski; D Coombs; D Baly; F Kabbinavar; D Slamon
Journal:  Oncogene       Date:  1999-04-01       Impact factor: 9.867

7.  Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Authors:  Harold J Burstein; Lyndsay N Harris; P Kelly Marcom; Rosemary Lambert-Falls; Kathleen Havlin; Beth Overmoyer; Robert J Friedlander; Janet Gargiulo; Rochelle Strenger; Charles L Vogel; Paula D Ryan; Mathew J Ellis; Raquel A Nunes; Craig A Bunnell; Susana M Campos; Michele Hallor; Rebecca Gelman; Eric P Winer
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

8.  Occult breast cancer presenting with axillary metastases. Updated management.

Authors:  P L Baron; M P Moore; D W Kinne; F C Candela; M P Osborne; J A Petrek
Journal:  Arch Surg       Date:  1990-02

Review 9.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

10.  Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung.

Authors:  D B Weiner; J Nordberg; R Robinson; P C Nowell; A Gazdar; M I Greene; W V Williams; J A Cohen; J A Kern
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

View more
  1 in total

Review 1.  "Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"?

Authors:  Stefan Kolling; Ferdinando Ventre; Elena Geuna; Melissa Milan; Alberto Pisacane; Carla Boccaccio; Anna Sapino; Filippo Montemurro
Journal:  Front Oncol       Date:  2020-01-17       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.